References
- Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. doi:https://doi.org/10.3322/caac.21660
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA A Cancer J Clin. 2020;70(1):7–30. doi:https://doi.org/10.3322/caac.21590
- Dekker E, Tanis PJ, Vleugels JLA, Kasi PM, Wallace MB. Colorectal cancer. Lancet. 2019;394(10207):1467–80. doi:https://doi.org/10.1016/S0140-6736(19)32319-0
- Markowitz SD, Bertagnolli MM. Molecular origins of cancer: molecular basis of colorectal cancer. N Engl J Med. 2009;361(25):2449–60. doi:https://doi.org/10.1056/NEJMra0804588
- American Cancer Society. Colorectal cancer facts and figures 2020–2022. Atlanta: American Cancer Society Inc.; 2020. p. 11.
- Lane DP. Cancer. p53, guardian of the genome. Nature. 1992;358(6381):15–6. doi:https://doi.org/10.1038/358015a0
- Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C, Xie M, Zhang Q, McMichael JF, Wyczalkowski MA, et al. Mutational landscape and significance across 12 major cancer types. Nature. 2013;502(7471):333–9. doi:https://doi.org/10.1038/nature12634
- Olivier M, Hollstein M, Hainaut P. TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol. 2010;2(1):a001008. doi:https://doi.org/10.1101/cshperspect.a001008
- Mantovani F, Collavin L, Del Sal G. Mutant p53 as a guardian of the cancer cell. Cell Death Differ. 2019;26(2):199–212. doi:https://doi.org/10.1038/s41418-018-0246-9
- Brannon AR, Vakiani E, Sylvester BE, Scott SN, McDermott G, Shah RH, Kania K, Viale A, Oschwald DM, Vacic V, et al. Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions. Genome Biol. 2014;15(8):454–64. doi:https://doi.org/10.1186/s13059-014-0454-7
- Hientz K, Mohr A, Bhakta-Guha D, Efferth T. The role of p53 in cancer drug resistance and targeted chemotherapy. Oncotarget. 2017;8(5):8921–46. doi:https://doi.org/10.18632/oncotarget.13475
- Grassilli E, Narloch R, Federzoni E, Ianzano L, Pisano F, Giovannoni R, Romano G, Masiero L, Leone BE, Bonin S, et al. Inhibition of GSK3B bypass drug resistance of p53-null colon carcinomas by enabling necroptosis in response to chemotherapy. Clin Cancer Res. 2013;19(14):3820–31. doi:https://doi.org/10.1158/1078-0432.CCR-12-3289
- Dabiri Y, Kalman S, Gürth C, Kim JY, Mayer V, Cheng X. The essential role of TAp73 in bortezomib-induced apoptosis in p53-deficient colorectal cancer cells. Sci Rep. 2017;7(1):5423. doi:https://doi.org/10.1038/s41598-017-05813-z
- Marcus JM, Burke RT, Doak AE, Park S, Orth JD. Loss of p53 expression in cancer cells alters cell cycle response after inhibition of exportin-1 but does not prevent cell death. Cell Cycle. 2018;17(11):1329–44. doi:https://doi.org/10.1080/15384101.2018.1480224
- Gordziel C, Bratsch J, Moriggl R, Knosel T, Friedrich K. Both STAT1 and STAT3 are favourable prognostic determinants in colorectal carcinoma. Br J Cancer. 2013;109(1):138–46. doi:https://doi.org/10.1038/bjc.2013.274
- Wang SW, Sun YM. The IL-6/JAK/STAT3 pathway: potential therapeutic strategies in treating colorectal cancer (review). Int J Oncol. 2014;44(4):1032–40. doi:https://doi.org/10.3892/ijo.2014.2259
- Corvinus FM, Orth C, Moriggl R, Tsareva SA, Wagner S, Pfitzner EB, Baus D, Kaufmann R, Huber LA, Zatloukal K, et al. Persistent STAT3 activation in colon cancer is associated with enhanced cell proliferation and tumor growth. Neoplasia. 2005;7(6):545–55. doi:https://doi.org/10.1593/neo.04571
- Lassmann S, Schuster I, Walch A, Göbel H, Jütting U, Makowiec F, Hopt U, Werner M. STAT3 mRNA and protein expression in colorectal cancer: effects on STAT3-inducible targets linked to cell survival and proliferation. J Clin Pathol. 2006;60(2):173–9. doi:https://doi.org/10.1136/jcp.2005.035113
- Johnston PA, Grandis JR. STAT3 signaling: anticancer strategies and challenges. Mol Interv. 2011;11(1):18–26. doi:https://doi.org/10.1124/mi.11.1.4
- Lim HJ, Jin HG, Woo ER, Lee SK, Kim HP. The root barks of Morus alba and the flavonoid constituents inhibit airway inflammation. J Ethnopharmacol. 2013;149(1):169–75. doi:https://doi.org/10.1016/j.jep.2013.06.017
- Chan EW, Lye PY, Wong SK. Phytochemistry, pharmacology, and clinical trials of Morus alba. Chin J Nat Med. 2016;14(1):17–30. doi:https://doi.org/10.3724/SP.J.1009.2016.00017
- Jung JW, Park JH, Lee YG, Seo KH, Oh EJ, Lee DY, Lim DW, Han D, Baek NI. Three new isoprenylated flavonoids from the root bark of Morus alba. Molecules. 2016;21(9):1112. doi:https://doi.org/10.3390/molecules21091112
- Cao YG, Zheng XK, Yang FF, Li F, Qi M, Zhang YL, Zhao X, Kuang HX, Feng WS. Two new phenolic constituents from the root bark of Morus alba L. and their cardioprotective activity. Nat Prod Res. 2018;32(4):391–8. doi:https://doi.org/10.1080/14786419.2017.1309535
- Lee HJ, Ryu J, Park SH, Woo ER, Kim AR, Lee SK, Kim YS, Kim JO, Hong JH, Lee CJ. Effects of Morus alba L. and natural products including morusin on in vivo secretion and in vitro production of airway MUC5AC mucin. Tuberc Respir Dis. 2014;77(2):65–72. doi:https://doi.org/10.4046/trd.2014.77.2.65
- El-Beshbishy HA, Singab AN, Sinkkonen J, Pihlaja K. Hypolipidemic and antioxidant effects of Morus alba L. (Egyptian mulberry) root bark fractions supplementation in cholesterol-fed rats. Life Sci. 2006;78(23):2724–33. doi:https://doi.org/10.1016/j.lfs.2005.10.010
- Du J, He ZD, Jiang RW, Ye WC, Xu HX, But PPH. Antiviral flavonoids from the root bark of Morus alba L. Phytochemistry. 2003;62(8):1235–8. doi:https://doi.org/10.1016/S0031-9422(02)00753-7
- Kim HJ, Lee HJ, Jeong SJ, Lee HJ, Kim SH, Park EJ. Cortex Mori Radicis extract exerts antiasthmatic effects via enhancement of CD4(+)CD25(+)Foxp3(+) regulatory T cells and inhibition of Th2 cytokines in a mouse asthma model. J Ethnopharmacol. 2011;138(1):40–6. doi:https://doi.org/10.1016/j.jep.2011.08.021
- Kikuchi T, Nihei M, Nagai H, Fukushi H, Tabata K, Suzuki T, Akihisa T. Albanol A from the root bark of Morus alba L. induces apoptotic cell death in HL60 human leukemia cell line. Chem Pharm Bull. 2010;58(4):568–71. doi:https://doi.org/10.1248/cpb.58.568
- Eo HJ, Park JH, Park GH, Lee MH, Lee JR, Koo JS, Jeong JB. Anti-inflammatory and anti-cancer activity of mulberry (Morus alba L.) root bark. BMC Complement Med Ther. 2014;14:200.
- Kwon YH, Bishayee K, Rahman A, Hong JS, Lim SS, Huh SO. Morus alba accumulates reactive oxygen species to initiate apoptosis via FOXO-caspase 3-dependent pathway in neuroblastoma cells. Mol Cells. 2015;38(7):630–7. doi:https://doi.org/10.14348/molcells.2015.0030
- Min TR, Park HJ, Park MN, Kim B, Park SH. The root bark of Morus alba L. suppressed the migration of human non-small cell lung cancer cells through inhibition of epithelial–mesenchymal transition mediated by STAT3 and Src. IJMS. 2019;20(9):2244. doi:https://doi.org/10.3390/ijms20092244
- Nam SY, Yi HK, Lee JC, Kim JC, Song CH, Park JW, Lee DY, Kim JS, Hwang PH. Cortex mori extract induces cancer cell apoptosis through inhibition of microtubule assembly. Arch Pharm Res. 2002;25(2):191–6. doi:https://doi.org/10.1007/BF02976562
- Park S-H, Chi GY, Eom HS, Kim G-Y, Hyun JW, Kim W-J, Lee S-J, Yoo YH, Choi YH. Role of autophagy in apoptosis induction by methylene chloride extracts of Mori cortex in NCI-H460 human lung carcinoma cells. Int J Oncol. 2012;40(6):1929–40. doi:https://doi.org/10.3892/ijo.2012.1386
- Park HJ, Chi GY, Choi YH, Park SH. The root bark of Morus alba L. regulates tumor-associated macrophages by blocking recruitment and M2 polarization of macrophages. Phytother Res. 2020;34(12):3333–44. doi:https://doi.org/10.1002/ptr.6783
- Klein EA, Assoian RK. Transcriptional regulation of the cyclin D1 gene at a glance. J Cell Sci. 2008;121(23):3853–7. doi:https://doi.org/10.1242/jcs.039131
- Boidot R, Végran F, Lizard-Nacol S. Transcriptional regulation of the survivin gene. Mol Biol Rep. 2014;41(1):233–40. doi:https://doi.org/10.1007/s11033-013-2856-0
- Park HJ, Min TR, Chi GY, Choi YH, Park SH. Induction of apoptosis by morusin in human non-small cell lung cancer cells by suppression of EGFR/STAT3 activation. Biochem Biophys Res Commun. 2018;505(1):194–200. doi:https://doi.org/10.1016/j.bbrc.2018.09.085
- Yan C, Lu D, Hai T, Boyd DD. Activating transcription factor 3, a stress sensor, activates p53 by blocking its ubiquitination. Embo J. 2005;24(13):2425–35. doi:https://doi.org/10.1038/sj.emboj.7600712
- Lim S-L, Park S-Y, Kang S, Park D, Kim S-H, Um J-Y, Jang H-J, Lee J-H, Jeong C-H, Jang J-H, et al. Morusin induces cell death through inactivating STAT3 signaling in prostate cancer cells. Am J Cancer Res. 2015;5(1):289–99.
- Lin WL, Lai DY, Lee YJ, Chen NF, Tseng TH. Antitumor progression potential of morusin suppressing STAT3 and NFκB in human hepatoma SK-Hep1 cells. Toxicol Lett. 2015;232(2):490–8. doi:https://doi.org/10.1016/j.toxlet.2014.11.031
- Park D, Ha IJ, Park S-Y, Choi M, Lim S-L, Kim S-H, Lee J-H, Ahn KS, Yun M, Lee S-G. Morusin induces TRAIL sensitization by regulating EGFR and DR5 in human glioblastoma cells. J Nat Prod. 2016;79(2):317–23. doi:https://doi.org/10.1021/acs.jnatprod.5b00919
- Kim K, Shin EA, Jung JH, Park JE, Kim DS, Shim BS, Kim SH. Ursolic acid induces apoptosis in colorectal cancer cells partially via upregulation of MicroRNA-4500 and inhibition of JAK2/STAT3 phosphorylation. IJMS. 2018;20(1):114. doi:https://doi.org/10.3390/ijms20010114
- Gao L, Wang L, Sun Z, Li H, Wang Q, Yi C, Wang X. Morusin shows potent antitumor activity for human hepatocellular carcinoma in vitro and in vivo through apoptosis induction and angiogenesis inhibition. Drug Des Dev Ther. 2017;11:1789–802. doi:https://doi.org/10.2147/DDDT.S138320
- Pathak AK, Bhutani M, Nair AS, Ahn KS, Chakraborty A, Kadara H, Guha S, Sethi G, Aggarwal BB. Ursolic acid inhibits STAT3 activation pathway leading to suppression of proliferation and chemosensitization of human multiple myeloma cells. Mol Cancer Res. 2007;5(9):943–55. doi:https://doi.org/10.1158/1541-7786.MCR-06-0348
- Wang W, Zhao C, Jou D, Lü J, Zhang C, Lin L, Lin J. Ursolic acid inhibits the growth of colon cancer-initiating cells by targeting STAT3. Anticancer Res. 2013;33(10):4279–84.
- Liu T, Ma H, Shi W, Duan J, Wang Y, Zhang C, Li C, Lin J, Li S, Lv J, et al. Inhibition of STAT3 signaling pathway by ursolic acid suppresses growth of hepatocellular carcinoma. Int J Oncol. 2017;51(2):555–62. doi:https://doi.org/10.3892/ijo.2017.4035
- Li W, Zhang H, Nie M, Tian Y, Chen X, Chen C, Chen H, Liu R. Ursolic acid derivative FZU-03,010 inhibits STAT3 and induces cell cycle arrest and apoptosis in renal and breast cancer cells. Acta Biochim Biophys Sin (Shanghai)). 2017;49(4):367–73. doi:https://doi.org/10.1093/abbs/gmx012
- Pandey MK, Sung B, Aggarwal BB. Betulinic acid suppresses STAT3 activation pathway through induction of protein tyrosine phosphatase SHP-1 in human multiple myeloma cells. Int J Cancer. 2010;127(2):282–92. doi:https://doi.org/10.1002/ijc.25059
- Zeng A-Q, Yu Y, Yao Y-Q, Yang F-F, Liao M, Song L-J, Li Y-L, Yu Y, Li Y-J, Deng Y-L, et al. Betulinic acid impairs metastasis and reduces immunosuppressive cells in breast cancer models. Oncotarget. 2018;9(3):3794–804. doi:https://doi.org/10.18632/oncotarget.23376
- Shin J, Lee HJ, Jung DB, Jung JH, Lee HJ, Lee EO, Lee SG, Shim BS, Choi SH, Ko SG, et al. Suppression of STAT3 and HIF-1 alpha mediates anti-angiogenic activity of betulinic acid in hypoxic PC-3 prostate cancer cells. PLoS One. 2011;6(6):e21492. doi:https://doi.org/10.1371/journal.pone.0021492
- Zugowski C, Lieder F, Muller A, Gasch J, Corvinus FM, Moriggl R, Friedrich K. STAT3 controls matrix metalloproteinase-1 expression in colon carcinoma cells by both direct and AP-1-mediated interaction with the MMP-1 promoter. Biol Chem. 2011;392(5):449–59. doi:https://doi.org/10.1515/BC.2011.038
- Rokavec M, Öner MG, Li H, Jackstadt R, Jiang L, Lodygin D, Kaller M, Horst D, Ziegler PK, Schwitalla S, et al. IL-6R/STAT3/miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis. J Clin Invest. 2014;124(4):1853–67. doi:https://doi.org/10.1172/JCI73531
- Wang T, Lin F, Sun X, Jiang L, Mao R, Zhou S, Shang W, Bi R, Lu F, Li S. HOXB8 enhances the proliferation and metastasis of colorectal cancer cells by promoting EMT via STAT3 activation. Cancer Cell Int. 2019;19(1):3. doi:https://doi.org/10.1186/s12935-018-0717-6
- Spitzner M, Roesler B, Bielfeld C, Emons G, Gaedcke J, Wolff HA, Rave-Fränk M, Kramer F, Beissbarth T, Kitz J, et al. Grade M: STAT3 inhibition sensitizes colorectal cancer to chemoradiotherapy in vitro and in vivo. Int J Cancer. 2014;134(4):997–1007. doi:https://doi.org/10.1002/ijc.28429
- Zhang Q, Liu R-X, Chan K-W, Hu J, Zhang J, Wei L, Tan H, Yang X, Liu H. Exosomal transfer of p-STAT3 promotes acquired 5-FU resistance in colorectal cancer cells. J Exp Clin Cancer Res. 2019;38(1):320. doi:https://doi.org/10.1186/s13046-019-1314-9
- Wei C, Yang C, Wang S, Shi D, Zhang C, Lin X, Liu Q, Dou R, Xiong B. Crosstalk between cancer cells and tumor associated macrophages is required for mesenchymal circulating tumor cell-mediated colorectal cancer metastasis. Mol Cancer. 2019;18(1):64. doi:https://doi.org/10.1186/s12943-019-0976-4
- Heichler C, Scheibe K, Schmied A, Geppert CI, Schmid B, Wirtz S, Thoma O-M, Kramer V, Waldner MJ, Büttner C, et al. STAT3 activation through IL-6/IL-11 in cancer-associated fibroblasts promotes colorectal tumour development and correlates with poor prognosis. Gut. 2020;69(7):1269–82. doi:https://doi.org/10.1136/gutjnl-2019-319200